The University of Chicago Header Logo

Connection

James Millis to Tacrolimus

This is a "connection" page, showing publications James Millis has written about Tacrolimus.
Connection Strength

1.247
  1. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant. 2014 Feb; 14(2):356-66.
    View in: PubMed
    Score: 0.429
  2. Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy. Transplant Proc. 1997 Feb-Mar; 29(1-2):1549.
    View in: PubMed
    Score: 0.132
  3. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation. 1996 May 15; 61(9):1365-9.
    View in: PubMed
    Score: 0.126
  4. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. Transplant Proc. 1996 Apr; 28(2):1014.
    View in: PubMed
    Score: 0.125
  5. Liver transplantation at the University of Chicago. Clin Transpl. 1999; 231-8.
    View in: PubMed
    Score: 0.038
  6. Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach. Transplant Proc. 1998 Jun; 30(4):1234-5.
    View in: PubMed
    Score: 0.036
  7. Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen. Transplant Proc. 1998 Jun; 30(4):1249-50.
    View in: PubMed
    Score: 0.036
  8. Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. Transplant Proc. 1998 Jun; 30(4):1378-9.
    View in: PubMed
    Score: 0.036
  9. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. Transplant Proc. 1998 Jun; 30(4):1538-40.
    View in: PubMed
    Score: 0.036
  10. Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation. Transplant Proc. 1998 Mar; 30(2):507-8.
    View in: PubMed
    Score: 0.036
  11. Reversal of accelerated renal allograft rejection with FK 506. Clin Transplant. 1997 Aug; 11(4):251-4.
    View in: PubMed
    Score: 0.034
  12. Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal. Transplant Proc. 1997 Feb-Mar; 29(1-2):307.
    View in: PubMed
    Score: 0.033
  13. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. Transplantation. 1996 Oct 15; 62(7):906-10.
    View in: PubMed
    Score: 0.032
  14. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation. Clin Transplant. 1996 Aug; 10(4):323-32.
    View in: PubMed
    Score: 0.032
  15. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. Transplant Proc. 1996 Apr; 28(2):998-9.
    View in: PubMed
    Score: 0.031
  16. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. Transplantation. 1995 Sep 27; 60(6):554-8.
    View in: PubMed
    Score: 0.030
  17. Liver transplantation in the first three months of life. Transplantation. 1998 Sep 15; 66(5):606-9.
    View in: PubMed
    Score: 0.009
  18. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation. 1996 Aug 15; 62(3):370-5.
    View in: PubMed
    Score: 0.008
  19. Living-donor liver transplantation at UCLA. Am J Surg. 1995 May; 169(5):529-32.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.